Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) reported positive interim results from a Phase 2 study of ACH-3102 sending the stock price soaring $2.74 to close at $12.85.
Positive interim results for Achillion Pharmaceuticals
November 10, 2014 at 16:29 PM EST
